Myositis Clinical Trials

58 recruitingLast updated: June 18, 2026

There are 58 actively recruiting myositis clinical trials across 38 countries. Studies span Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1. Top locations include Paris, France, Boston, Massachusetts, United States, Miami, Florida, United States. Updated daily from ClinicalTrials.gov.


Myositis Trials at a Glance

58 actively recruiting trials for myositis are listed on ClinicalTrialsFinder across 6 cities in 38 countries. The largest study group is Phase 1 with 13 trials, with the heaviest enrollment activity in Paris, Boston, and Miami. Lead sponsors running myositis studies include Assistance Publique - Hôpitaux de Paris, Chongqing Precision Biotech Co., Ltd, and National Institute of Environmental Health Sciences (NIEHS).

Browse myositis trials by phase

Treatments under study

About Myositis Clinical Trials

Looking for clinical trials for Myositis? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myositis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myositis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 58 trials

Recruiting
Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting

Environmental Risk Factors for the Anti-synthetase Syndrome

DermatomyositisPolymyositisMyositis+2 more
National Institute of Environmental Health Sciences (NIEHS)580 enrolled8 locationsNCT01276470
Recruiting
Phase 1

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

SLE (Systemic Lupus)Diffuse Cutaneous Systemic SclerosisSystemic Sclerosis+4 more
CRISPR Therapeutics80 enrolled14 locationsNCT06925542
Recruiting
Phase 2

FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)

Dermatomyositis (DM)Juvenile Dermatomyositis (JDM)
National Institute of Environmental Health Sciences (NIEHS)300 enrolled1 locationNCT07111065
Recruiting

Adult and Juvenile Myositis

DermatomyositisInclusion Body MyositisPolymyositis
National Institute of Environmental Health Sciences (NIEHS)1,200 enrolled4 locationsNCT00017914
Recruiting

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

lichen planusAtopic DermatitisHidradenitis Suppurativa+9 more
Assistance Publique - Hôpitaux de Paris830 enrolled1 locationNCT06599411
Recruiting
Phase 2Phase 3

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

DermatomyositisIdiopathic Inflammatory MyopathyAnti-synthetase Syndrome+5 more
Cabaletta Bio74 enrolled35 locationsNCT06154252
Recruiting

Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositis

Autoinflammatory DiseaseJuvenile Dermatomyositis
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)5,000 enrolled1 locationNCT00059748
Recruiting
Phase 3

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

Myositis
Pfizer318 enrolled146 locationsNCT05895786
Recruiting
Phase 3

Baricitinib in Patients With Relapsing or naïve Dermatomyositis

Dermatomyositis
Assistance Publique - Hôpitaux de Paris62 enrolled1 locationNCT04972760
Recruiting
Phase 3

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

Polymyositis, Dermatomyositis
AstraZeneca240 enrolled236 locationsNCT06455449
Recruiting
Phase 2

Ruxolitinib Treatment in Inclusion Body Myositis

Inclusion Body Myositis, Sporadic
Assistance Publique - Hôpitaux de Paris80 enrolled21 locationsNCT06536166
Recruiting
Phase 2

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

SclerodermaRheumatoid Arthritis (RA)Sjogren Syndrome+6 more
Artiva Biotherapeutics, Inc.90 enrolled52 locationsNCT06991114
Recruiting
Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Lupus Nephritis+2 more
Fate Therapeutics244 enrolled21 locationsNCT06308978
Recruiting
Phase 3

A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

DermatomyositisPolymyositis
Pfizer211 enrolled24 locationsNCT06698796
Recruiting
Phase 2

Intralesional Injection of STS in Treatment of Calcinosis

DermatomyositisSystemic Sclerosis (SSc)Mixed Connective Tissue Disease (MCTD)+1 more
Robyn T. Domsic, MD, MPH20 enrolled1 locationNCT06672822
Recruiting
Phase 2Phase 3

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

Idiopathic Inflammatory Myositis (IIM)DERMATOMYOSITIS OR POLYMYOSITIS
Restem, LLC.40 enrolled2 locationsNCT07160205
Recruiting
Not Applicable

Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases

Rheumatoid ArthritisSystemic Lupus ErythematosusDermatomyositis+1 more
The First Affiliated Hospital with Nanjing Medical University72 enrolled1 locationNCT07558850
Recruiting
Phase 1Phase 2

Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

Juvenile Myasthenia GravisANCA Associated Vasculitis (AAV)Juvenile Dermatomyositis+1 more
Cartesian Therapeutics50 enrolled2 locationsNCT07089121
Recruiting
Phase 1

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Antiphospholipid Syndrome (APS)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)+3 more
Chugai Pharmaceutical144 enrolled69 locationsNCT06371417